Xenetic Biosciences Inc. (3XB0)
XMUN 
NASDAQ (CM) Primary XMUN Summary
3XB0 Chart
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates
Xenetic Biosciences (XBIO) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.83 per share a year ago.
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Reid Bissonnette, Ph.D, Executive Consultant for Translational Research and Development at Xenetic, discusses extension of its Research Agreement with the University of Virginia for the advancement of its DNase-Based oncology platform Watch the "What This Means" video here FRAMINGHAM, MA / ACCESSWIRE / December 17, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that announced that Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic participated in a Virtual Investor "What This Means" segment As part of the segment, Dr. Bissonnette discussed the Company's recently announced extension of its Research Agreement with the University of Virginia for the advancement of its DNase-Based oncology platform. The Virtual Investor "What This Means" segment featuring Xenetic is now available here.
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Company continuing to advance DNase-based oncology program towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / December 16, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat cancers, today announced it has extended its previously announced Research Funding Agreement (the "Agreement") with the University of Virginia ("UVA") to advance the development of its systemic DNase program through 2025. Xenetic's DNase-based oncology platform is designed to target neutrophil extracellular traps (NETs), which are weblike structures composed of extracellular chromatin coated with histones and other proteins.
Xenetic Biosciences Inc. (3XB0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Xenetic Biosciences Inc. ever had a stock split?
Xenetic Biosciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | James F. Parslow CEO | XMUN Exchange | US9840156023 ISIN |
| US Country | 2 Employees | - Last Dividend | 15 May 2023 Last Split | 30 Jun 2014 IPO Date |
Overview
Xenetic Biosciences, Inc. is a pioneering biopharmaceutical company deeply immersed in the discovery, research, and development of innovative biologic drugs and oncology therapeutics. At the heart of its mission is the advancement of XCART, a state-of-the-art personalized chimeric antigen receptor T cell (CAR T) platform technology. This groundbreaking technology is specifically engineered to target patient-specific tumor neoantigens, offering a highly personalized approach to cancer treatment. Positioned at the forefront of cell-based therapeutics, Xenetic Biosciences focuses on targeting the B-cell receptor present on the surface of an individual patient’s malignant tumor cells. This strategic concentration seeks to revolutionize the treatment of B-cell lymphomas. Headquartered in Framingham, Massachusetts, Xenetic Biosciences leverages its proprietary PolyXen drug delivery platform to form strategic partnerships with key players in the biotechnology and pharmaceutical sectors. Collaborative agreements with industry giants such as Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC, empower Xenetic to broaden its impact and extend its reach in the fight against cancer.
Products and Services
- XCART Platform Technology:
A cutting-edge personalized CAR T platform technology devised to target patient-specific tumor neoantigens. This innovation is aimed at offering a highly personalized treatment regimen by engineering T cells to specifically target the unique characteristics of a patient’s tumor, particularly for the treatment of B-cell lymphomas.
- Cell-Based Therapeutics:
Focusing on the advancement of treatments targeting the B-cell receptor on the surface of individual patient's malignant tumor cells. Xenetic Biosciences’ commitment to this area signifies a promising avenue for the treatment of B-cell lymphomas, emphasizing a personalized approach to oncology therapeutics.
- PolyXen Drug Delivery Platform:
Xenetic Biosciences’ proprietary drug delivery technology, designed to enhance the bio-availability, safety, and efficacy of biologic drugs. The PolyXen platform is utilized in partnership with leading biotechnology and pharmaceutical companies to optimize the therapeutic delivery of biologic agents.
Contact Information
